MOLECULAR MODELING OF ASPERLICIN DERIVED CHOLECYSTOKININ-A RECEPTOR ANTAGONISTS

被引:3
|
作者
VANDERBENT, A
TERLAAK, AM
IJZERMAN, AP
SOUDIJN, W
机构
[1] Division of Medicinal Chemistry, Center for Bio-Pharmaceutical Sciences
关键词
CHOLECYSTOKININ RECEPTOR; CCKA RECEPTOR ANTAGONISTS; MOLECULAR MODELING; DEVAZEPIDE; L-364,718;
D O I
10.1016/0922-4106(92)90050-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The C3-substituted benzodiazepines derived from asperlicin, e.g. devazepide (L-364,718, MK-329), constitute the most potent class of cholecystokinin A-type (CCK(A)) receptor antagonists. In order to gain insight into the prerequisites for binding, we examined the conformational properties of both potent and weak representatives of this class with computer assisted molecular modelling (CAMM) techniques. The CAMM results indicate that the binding site for the C3-substituents is a planar slot on the CCK(A) receptor surface and, in addition, allow the proposal of a model which describes the relative binding mode of the less potent R isomers versus that of the S isomers. The latter model illustrates the unique spatial properties of the benzodiazepine moiety, which we suggest functions primarily as an invertible core which assures an optimal arrangement of attached substituents.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 50 条
  • [31] Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist
    Fukamizu, Y
    Nakajima, T
    Kimura, K
    Kanda, H
    Fujii, M
    Saito, T
    Kasai, H
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1998, 48 (01): : 58 - 64
  • [32] MOLECULAR MODELING OF ADENOSINE RECEPTOR ANTAGONISTS
    VANGALEN, PJM
    VANVLIJMEN, HWT
    IJZERMAN, AP
    SOUDIJN, W
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1987, 9 (06) : 339 - 339
  • [33] The action of the cholecystokinin-A receptor antagonist, devazepide, on the digestive system of the chicken
    Furuse, M
    Choi, YH
    Satoh, S
    Okumura, J
    EXPERIENTIA, 1996, 52 (04): : 353 - 356
  • [34] Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor
    Yamamoto, Y
    Akiyoshi, J
    Kiyota, A
    Katsuragi, S
    Tsutsumi, T
    Isogawa, K
    Nagayama, H
    BRAIN RESEARCH BULLETIN, 2000, 53 (06) : 789 - 792
  • [35] Cholecystokinin-A receptor messenger RNA expression in human pancreatic cancer
    Moonka, R
    Zhou, WG
    Bell, RH
    JOURNAL OF GASTROINTESTINAL SURGERY, 1999, 3 (02) : 134 - 140
  • [36] Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese
    Miyasaka, K
    Yoshida, Y
    Matsushita, S
    Higuchi, S
    Shirakawa, O
    Shimokata, H
    Funakoshi, A
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2004, 127B (01): : 78 - 80
  • [37] Neostriatal neurons of rats can be influenced by cholecystokinin-A receptor agonists
    Davidowa, H
    Wetzel, K
    Henklein, P
    NEUROPEPTIDES, 1997, 31 (03) : 231 - 235
  • [38] PANCREATIC ATROPHY IN RATS PRODUCED BY THE CHOLECYSTOKININ-A RECEPTOR ANTAGONIST DEVAZEPIDE
    NYLANDER, AG
    CHEN, D
    IHSE, I
    REHFELD, JF
    HAKANSON, R
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (09) : 743 - 747
  • [39] Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese
    Miyasaka, K
    Yoshida, Y
    Ohta, M
    Kanai, S
    Hosoya, H
    Yamakawa, N
    Shirakawa, O
    Matsushita, S
    Higuchi, S
    Funakoshi, A
    GASTROENTEROLOGY, 2003, 124 (04) : A300 - A300
  • [40] CHOLECYSTOKININ-DOPAMINE RECEPTOR INTERACTIONS AS STUDIED WITH CHOLECYSTOKININ RECEPTOR ANTAGONISTS
    MURPHY, RB
    DRUG DEVELOPMENT RESEARCH, 1984, 4 (04) : 457 - 457